IRD
Opus Genetics Inc.

345
Loading...
Loading...
News
all
press releases
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +52.00% and -12.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +51.61% and +118.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·2mo ago
News Placeholder
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
Zacks·4mo ago
News Placeholder
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Zacks·4mo ago
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
chainwire·4mo ago

Latest IRD News

View

Advertisement. Remove ads.

Advertisement. Remove ads.